首页> 外文学位 >Novel particulate antibiotic-loaded platforms as sustained drug delivery systems for bone infection treatment
【24h】

Novel particulate antibiotic-loaded platforms as sustained drug delivery systems for bone infection treatment

机译:新型颗粒抗生素平台作为用于骨感染治疗的持续药物输送系统

获取原文
获取原文并翻译 | 示例

摘要

The most common infecting microorganisms in bone infections are staphylococci, namely Staphylococcus aureus and Staphylococcus epidermidis. Conventionally, complicated bone infections caused by Gram-positive bacteria are treated with vancomycin. However, emergence of resistant staphylococci to vancomycin led to the increased use of daptomycin, which is bactericidal against resistant staphylococci. However, in severe bone infections, daptomycin efficacy is often limited, due to insufficient drug bioavailability at the infected site and biofilm tolerance; hence novel approaches are needed to enhance daptomycin antibiofilm effect. Over the last decades, polymeric nano-/microparticles have emerged as a worthy strategy to enhance the antibiofilm effect of clinically available antibiotics. In this context, daptomycin was encapsulated into polymeric microparticles composed by poly(methyl methacrylate (PMMA), PMMA-Eudragit RL 100 (EUD) and poly-caprolactone (PCL). Vancomycin-loaded microparticles were also prepared as controls. All particles were obtained by an optimised double emulsion-solvent evaporation method and subsequently freeze-died. The final particles presented a spherical morphology within the micrometre size range, high drug encapsulation and yield of preparation. Additionally, the effect of the microparticles on cell viability of ISO-compliant cells, fibroblasts, and osteoblasts was tested. Although some formulations induced a slight decrease in cell viability, none of them was considered cytotoxic. Bearing in mind the main objective of this work, daptomycin-loaded PMMA-EUD and PCL microparticles presented the highest in vitro drug release, with concentrations above the minimal inhibitory and bactericidal concentration of the tested strains. Nevertheless, the antibacterial activity of all formulations was assessed against planktonic and sessile clinically relevant staphylococci by isothermal microcalorimetry (IMC). Further characterization of microparticles-biofilm interaction, as well as assessment of their effect on biofilm size, structure and metabolic state, was performed by fluorescence in situ hybridization (FISH). Daptomycin-loaded PMMA-EUD and PCL microparticles proved to be the most effective against the tested strains with high antibiofilm activity. Finally, the microencapsulation of daptomycin into polymeric carriers proved to be an advantageous approach, thus making them potential candidates as sustained drug delivery systems for bone infections treatment. In addition, the innovative combination of IMC with FISH was essential in order to gain further insights on the antibiofilm effects of microparticulate systems, as well as on their interaction with sessile bacteria.
机译:骨感染中最常见的感染微生物是葡萄球菌,即金黄色葡萄球菌和表皮葡萄球菌。常规地,由万古霉素治疗由革兰氏阳性细菌引起的复杂的骨感染。然而,对万古霉素耐药的葡萄球菌的出现导致达托霉素的使用增加,达托霉素对耐药的葡萄球菌具有杀菌作用。但是,在严重的骨感染中,由于感染部位的药物生物利用度不足和生物膜耐受性不足,达托霉素的功效常常受到限制。因此需要新的方法来增强达托霉素的抗生物膜作用。在过去的几十年中,聚合纳米/微粒已经成为增强临床上可用抗生素的抗生物膜作用的有价值的策略。在这种情况下,达托霉素被封装在由聚甲基丙烯酸甲酯(PMMA),PMMA-Eudragit RL 100(EUD)和聚己内酯(PCL)组成的聚合物微粒中,还制备了载有万古霉素的微粒作为对照,获得了所有微粒。通过优化的双乳剂-溶剂蒸发法,然后冷冻干燥,最终的颗粒呈现出微米级范围内的球形形态,高的药物包封度和制剂的收率,此外,这些颗粒对符合ISO标准的细胞生存力的影响对细胞,成纤维细胞和成骨细胞进行了测试,尽管有些制剂会引起细胞活力的轻微降低,但没有一个被认为具有细胞毒性,因此,记住这项工作的主要目的,载有达托霉素的PMMA-EUD和PCL微粒在体外药物释放,其浓度高于被测菌株的最低抑菌和杀菌浓度。通过等温微量热法(IMC)评估了所有制剂对浮游和无临床意义的葡萄球菌的抗菌活性。通过荧光原位杂交(FISH)对微粒与生物膜的相互作用进行了进一步表征,并评估了它们对生物膜大小,结构和代谢状态的影响。负载达托霉素的PMMA-EUD和PCL微粒被证明对具有高抗生物膜活性的被测菌株最有效。最后,将达托霉素微囊化为聚合物载体被证明是一种有利的方法,因此使其成为潜在的候选药物,成为用于骨感染治疗的持续药物递送系统。此外,IMC与FISH的创新结合对于进一步了解微粒系统的抗生物膜作用以及它们与无柄细菌的相互作用至关重要。

著录项

  • 作者单位

    Universidade de Lisboa (Portugal).;

  • 授予单位 Universidade de Lisboa (Portugal).;
  • 学科 Pharmacology.;Management.
  • 学位 Ph.D.
  • 年度 2015
  • 页码 241 p.
  • 总页数 241
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号